Evaluating Digital Twins for Alzheimer’s Disease using Data from a Completed Phase 2 Clinical Trial

Complex Alzheimer’s Disease (AD) clinical trials that require a large number of subjects leads to long trial timelines and significant costs. Our novel methods can accelerate randomized clinical trials (RCT) by reducing the required number of subjects using a combination of deep learning-based predictive models and statistical methods while meeting regulatory requirements. Our method leverages historical control clinical data in a way that allows for faster trials without sacrificing the reliability of traditional RCT analyses. Read the abstract, originally presented at AAIC 2022, to learn more about how a Phase 2 study on crenezumab (the ABBY study, NCT01343966) in mild-to-moderate AD was used to retrospectively assess the validity of this approach for AD clinical trials and the potential impact on future studies.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.

How will AI transform the future of medicine?

White Papers

Prognostic digital twins overcome the limitations of external control arms in RCTs


European Medicines Agency Qualifies Unlearn’s AI-powered Method for Running Smaller, Faster Clinical Trials

PROCOVA procedure outlines a clear regulatory-qualified framework for implementing AI-generated prognostic digital twins in clinical trials
Both methods reduce control arm sizes, but only digital twins control for bias.
Hear from Charles Fisher, founder and CEO of Unlearn, in this on-demand webinar about how AI will transform the medical landscape of tomorrow.